Related Experiment Video

Updated: Sep 27, 2025

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

1.3K

Prospects of Disease-Modifying Osteoarthritis Drugs

Win Min Oo1

  • 1Department of Physical Medicine and Rehabilitation, Mandalay General Hospital, University of Medicine, Mandalay, Mandalay, Myanmar; Rheumatology Department, Royal North Shore Hospital, Institute of Bone and Joint Research, Kolling Institute, The University of Sydney, Sydney, Australia.

Clinics in Geriatric Medicine
|April 12, 2022
PubMed

Insights

Osteoarthritis treatments are lacking, but new disease-modifying drugs (DMOADs) targeting inflammation, bone, or cartilage are in development. Research opportunities exist to refine clinical trial designs for these promising osteoarthritis therapies.

Area of Science:

  • Rheumatology
  • Pharmacology
  • Clinical Trials

Background:

  • Osteoarthritis (OA) affects nearly 23% of the global population, presenting a significant disease burden.
  • Current OA treatments lack disease-modifying capabilities, highlighting an unmet medical need.
  • Developing disease-modifying osteoarthritis drugs (DMOADs) is a critical therapeutic goal.

Purpose of the Study:

  • To review active DMOAD candidates in Phase 2/3 clinical trials.
  • To analyze DMOAD development based on OA pathogenetic mechanisms (inflammation, bone, cartilage).
  • To identify challenges and research opportunities for OA drug development using the PICO framework.

Main Methods:

  • Review of DMOAD candidates in Phase 2/3 clinical trials.
  • Categorization of drug candidates by OA endotypes: inflammation-driven, bone-driven, and cartilage-driven.
  • Application of the PICO (Population, Intervention, Comparison, Outcome) approach to assess research questions.

Main Results:

  • Several DMOAD candidates targeting distinct OA pathogenetic mechanisms are progressing through clinical trials.
  • The review identifies specific challenges in current OA drug development pipelines.
  • Opportunities for optimizing research questions and trial design are highlighted.

Conclusions:

  • Active DMOAD candidates show promise for modifying osteoarthritis progression.
  • Strategic research, guided by endotype-specific mechanisms and PICO principles, is essential for successful OA drug development.
  • Addressing the unmet need for effective OA treatments requires continued innovation in clinical trial design and therapeutic strategies.
Keywords:
DMOADsDisease-modifying drugsIntra-articular therapy: endotypeOsteoarthritis

More Related Videos

Standardized Histomorphometric Evaluation of Osteoarthritis in a Surgical Mouse Model07:32

Standardized Histomorphometric Evaluation of Osteoarthritis in a Surgical Mouse Model

Published on: May 6, 2020

12.4K
Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs12:44

Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs

Published on: January 27, 2023

4.0K

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
46
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
248
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
622
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282